

1           **Supplementary material: Assessing the impact of mass**  
2           **testing during a novel infectious disease outbreak: The case**  
3           **of COVID-19**

4           **Authors**

5           Yang Ge<sup>1</sup>, Department of Epidemiology and Biostatistics, The University of Georgia, Athens,  
6           GA, USA, <https://orcid.org/0000-0001-5100-0703>

7           Brian Kenneth McKay, Department of Epidemiology and Biostatistics, The University of  
8           Georgia, Athens, GA, USA, <https://orcid.org/0000-0003-3859-7634>

9           Shengzhi Sun, Department of Environmental Health, Boston University School of Public Health,  
10          Boston, MA, USA.

11          Feng Zhang, Department of Biostatistics and Data Science, University of Texas Health Science  
12          Center at Houston, School of Public Health, Houston, TX, USA.

13          Andreas Handel<sup>2</sup>, Department of Epidemiology and Biostatistics, The University of Georgia,  
14          Athens, GA, USA, <http://orcid.org/0000-0002-4622-1146>

15          Corresponding author: *yang.ge@uga.edu*<sup>1</sup>, *ahandel@uga.edu*<sup>2</sup>

## 16 **Estimating $F$ and $P$ for a few pathogens**

17 The MSTI strategy we discuss here depends on values for the proportion,  $P$ , of individuals that  
18 show a set of symptoms who will be infected with the novel pathogen, and the risk of infection  
19 due to being at a testing site,  $F$ . Precise estimates for either of those quantities are unlikely to be  
20 available for any setting. However, if the right data is collected, it is possible to get decent  
21 estimates. Unfortunately, since MSTI has not been formally evaluated previously, the right kind  
22 of data is not available. As an alternative, we searched the literature and tried to find reports that  
23 had some data that would allow us to estimate  $F$  and  $P$  for a few pathogens. The following  
24 sections explain how we obtained those estimates. Due to the strong limitations with the data,  
25 these estimates should be considered very approximate and uncertain.

### 26 **Ebola**

27 One study [1] reports a scenario where 464 of 724 patients (64%) suspected to have Ebola virus  
28 disease (EVD) were found to have EVD. A similar fraction was reported for a different setting in  
29 another study [2], with 276 of 433 suspected patients (64%) having EVD. In [3], the fraction is  
30  $108/154 = 70\%$ . while [4] report  $822/2362=35\%$ . Based on these reports, we obtain an estimate  
31 for  $P$  in the range of 0.35-0.7.

32 To estimate  $F$ , we use data from [5], which reports that among a cohort of 543 patients who  
33 initially did not have EVD and were discharged, 18 later likely developed EDV. It is unclear if  
34 they got infected in the facility, but an upper bound would be  $18/543 = 0.03$ . In a similar study  
35 [6] found  $9/138=0.07$  as an upper bound. This leads to an estimate for  $F$  in the range of 0.03-  
36 0.07.

## 37 **Measles**

38 In [7], the authors analyzed four sets of data to determine confirmed measles cases among those  
39 having a clinical diagnosis and found those to be  $77/128=0.60$ ,  $1/26=0.04$ ,  $1/93=0.01$ ,  
40  $74/213=0.35$ . This leads to an estimate for  $P$  covering a wide range of 0.01-0.6.

41 To estimate  $F$ , we use data from [8], which reports a case where a single visit to an emergency  
42 department resulted in 12 cases. They do not report the number of exposed persons. If we make a  
43 guess of around 100, we obtain a risk of infection of  $12/100=0.12$ . Similarly, [9] report 4 cases  
44 caused by an ED visit of an infected patient. Again using a total size of around 100 for those  
45 exposed we get  $4/100=0.04$ . This leads to an estimate for  $F$  in the range of 0.04-0.12.

## 46 **COVID-19**


47 The least information is available for the current COVID-19 outbreak. Notes of a press  
48 conference held by National Health Commission of the People's Republic of China show there  
49 were 10261 total fever clinic visits in Wuhan on Jan 27, 2020 [10], with 315 confirmed cases  
50 reported next day [11]. Similarly, 12512 and 12568 total fever clinic visits occurred on Feb 3 and  
51 4 [12], with 1967 and 1766 confirmed cases reported the next day [13,14]. If we use the reported  
52 fever visits as indication of the total number of individuals showing respiratory symptoms and  
53 the next day reported cases as the number among those individuals who are infected with  
54 COVID-19, we obtain as estimates for  $P$  the values  $315/10261$ ,  $1967/12512$  and  $1766/12568$ ,  
55 which leads to an estimated range for  $P$  of 0.03-0.16.

56 To estimate  $F$ , we use data from [15], which reports that one patient infected 4 hospitalized  
57 patients in the same ward. We do not know the number of exposed persons in this ward. If we

58 take a range of 10-100, this would lead to risk of infection from  $4/10$  -  $4/100$  and thus  $F$  in the  
59 range of 0.04 - 0.4.

## 60 **Scenarios with non-perfect isolation**

61 In the main text, we considered the optimistic case where isolation following testing led to no  
62 further transmission and no mortality. Here, we explore how results change if instead isolation  
63 only reduced those quantities by some amount. As a reminder, the general expressions for  
64 transmission risk ratio (TRR) and mortality risk ratio (MRR) are given by  $TRR = T_S/T_H =$   
65  $R_I/R + (1 - P)F/P$  and  $MRR = M_S/M_H = M_I/M_0 + (1 - P)F/P$ . The figure explores  
66 scenarios ranging from isolation having very little effect on transmission and mortality risk and  
67 only reducing them by 10% (i.e.  $R_I = 0.9R$  and  $M_I = 0.9M$ ) up to a reduction of 90% (i.e.  $R_I =$   
68  $0.1R$  and  $M_I = 0.1M$ ). As expected, a smaller reduction in infection and mortality risk shrinks  
69 the range for which MSTI is a beneficial strategy.



70


Proportion of novel pathogen infections among symptomatic patients (P)

71 *Figure 1: Simulation of TRR and MRR in scenarios; A:  $R_I = 0.9R$ , B:  $R_I = 0.5R$ , C:  $R_I = 0.1R$ ,*

72 *D:  $M_I = 0.9M$ , E:  $M_I = 0.5M$ , F:  $M_I = 0.1M$*

## 73 **An explicit equation for the probability of infection**

74 The probability of infection,  $F$ , is expected to increase as the proportion of individuals infected  
75 with the novel pathogen increases and will saturate at some maximum value. This can be  
76 described by a simple function  $F = P/(K + P)$ , where  $K$  describes the strength of the infection  
77 control at the testing site. For small  $K$ ,  $F$  will eventually approach 1. For infection control  
78 strength of  $K = 1$ , the maximum risk of transmission, (if prevalence were to be  $P = 1$ ) would be  
79  $F = 0.5$ .



80

81 *Figure 2: MSTI associated infection risk,  $F$ , as a function of novel pathogen prevalence among*  
82 *symptomatic,  $P$ , given by  $F = P/(K + P)$  for different values of  $K$ .*

83 If we use  $F = P/(K + P)$  in our TRR and MRR equations, we find  $TRR = T_S/T_H = R_I/R +$

84  $(1 - P)/(K + P)$  and  $MRR = M_S/M_H = M_I/M_0 + (1 - P)/(K + P)$ . With the assumption of

85 perfect isolation ( $R_I = M_I = 0$ ), this becomes  $TRR = MRR = (1 - P)/(K + P)$ .

86 For MSTI to be useful, we need to have  $TRR = MRR < 1$ , and thus  $(K + P) > (1 - P)$  or  $K >$   
87  $1 - 2P$ . This shows that infection control needs to be strongest at  $K \geq 1$  for low prevalence, and  
88 once  $P \geq 0.5$ , even zero infection control will make MSTI beneficial. This corresponds to the  
89 main text discussion of keeping  $F < P$  for low prevalence, while the value of  $F$  does not matter  
90 once prevalence reaches 0.5.

91 Note that the infection control parameter  $K$  in our model is in arbitrary units without a clear way  
92 to connect and measure it for any specific setting. If any 2 of  $K$ ,  $F$  and  $P$  are known, the third  
93 quantity can be estimated. It is more likely that data can be obtained for infection risk  $F$ , instead  
94 of  $K$ , which is why we focused on  $F$  in the main text.

95 **References**

- 96 1. Lado M, Walker NF, Baker P, et al. Clinical features of patients isolated for suspected ebola  
97 virus disease at connaught hospital, freetown, sierra leone: A retrospective cohort study. *The*  
98 *Lancet infectious diseases* **2015**; 15:1024–1033.
- 99 2. Vogt F, Fitzpatrick G, Patten G, et al. Assessment of the msf triage system, separating patients  
100 into different wards pending ebola virus laboratory confirmation, kailahun, sierra leone, july to  
101 september 2014. *Eurosurveillance* **2015**; 20:30097.
- 102 3. Yan T, Mu J, Qin E, et al. Clinical characteristics of 154 patients suspected of having ebola  
103 virus disease in the ebola holding center of jui government hospital in sierra leone during the  
104 2014 ebola outbreak. *European journal of clinical microbiology & infectious diseases* **2015**;  
105 34:2089–2095.
- 106 4. Ingelbeen B, Bah EI, Decroo T, et al. Mortality among per negative admitted ebola suspects  
107 during the 2014/15 outbreak in conakry, guinea: A retrospective cohort study. *PloS one* **2017**;  
108 12.
- 109 5. Arkell P, Youkee D, Brown CS, et al. Quantifying the risk of nosocomial infection within  
110 ebola holding units: A retrospective cohort study of negative patients discharged from five ebola  
111 holding units in western area, sierra leone. *Tropical Medicine & International Health* **2017**;  
112 22:32–40.
- 113 6. Fitzpatrick G, Vogt F, Gbabai OM, et al. Describing readmissions to an ebola case  
114 management centre (cmc), sierra leone, 2014. *Eurosurveillance* **2014**; 19:20924.
- 115 7. Hutchins SS, Amler R, Maes EF, et al. Evaluation of the measles clinical case definition. *The*  
116 *Journal of infectious diseases* **2004**; 189:S153–S159.
- 117 8. Porretta A, Quattrone F, Aquino F, et al. A nosocomial measles outbreak in italy, february-  
118 april 2017. *Eurosurveillance* **2017**; 22.
- 119 9. Chen SY, Anderson S, Kutty PK, et al. Health care-associated measles outbreak in the united  
120 states after an importation: Challenges and economic impact. *Journal of Infectious Diseases*  
121 **2011**; 203:1517–1525.
- 122 10. National Health Commission. Transcript of the press conference on January 27, 2020-  
123 National Health Commission of the People’s Republic of China. Available at:  
124 <http://www.nhc.gov.cn/xcs/s3574/202001/50050057b6fe4a2b90763d95c4273ceb.shtml>.  
125 Accessed 5 February 2020.
- 126 11. Provincial Health Committee. Transcript of epidemic situation of new coronavirus infection  
127 in hubei on January 28, 2020. 2020. Available at:  
128 [http://wjw.hubei.gov.cn/fbjd/dtyw/202001/t20200129\\_2015921.shtml](http://wjw.hubei.gov.cn/fbjd/dtyw/202001/t20200129_2015921.shtml). Accessed 5 February  
129 2020.
- 130 12. National Health Commission. Transcript of the press conference on February 4, 2020-  
131 National Health Commission of the People’s Republic of China. 2020. Available at:

- 132 <http://www.nhc.gov.cn/wjw/xwdt/202002/35990d56cfcb43f4a70d7f9703b113c0.shtml>.  
133 Accessed 5 February 2020.
- 134 13. Provincial Health Committee. Transcript of epidemic situation of new coronavirus infection  
135 in hubei on February 3, 2020. 2020. Available at:  
136 [http://wjw.hubei.gov.cn/fbjd/dtyw/202002/t20200204\\_2018742.shtml](http://wjw.hubei.gov.cn/fbjd/dtyw/202002/t20200204_2018742.shtml). Accessed 5 February  
137 2020.
- 138 14. Provincial Health Committee. Transcript of epidemic situation of new coronavirus infection  
139 in hubei on February 4, 2020. 2020. Available at:  
140 [http://wjw.hubei.gov.cn/fbjd/dtyw/202002/t20200205\\_2019293.shtml](http://wjw.hubei.gov.cn/fbjd/dtyw/202002/t20200205_2019293.shtml). Accessed 5 February  
141 2020.
- 142 15. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019  
143 novel coronavirusInfected pneumonia in wuhan, china. *JAMA* **2020**;